Results 161 to 170 of about 21,815 (182)

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer. [PDF]

open access: yesFuture Oncol
Agarwal N   +20 more
europepmc   +1 more source

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer [PDF]

open access: yesNew England Journal of Medicine, 2020
BACKGROUND: Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while ...
Neal Shore   +2 more
exaly   +2 more sources

Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy [PDF]

open access: yesNew England Journal of Medicine, 2014
BACKGROUND: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy.
Anthony M Joshua   +2 more
exaly   +6 more sources

Enzalutamide With Standard First-Line Therapy in Metastatic Prostate Cancer

New England Journal of Medicine, 2019
Anthony M Joshua   +2 more
exaly  

Home - About - Disclaimer - Privacy